New registry tracks Real-World use of PFIC drug odevixibat
NCT ID NCT07588880
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This registry will follow 20 people in China with progressive familial intrahepatic cholestasis (PFIC) who are taking odevixibat (Bylvay) as part of their normal care. The goal is to see how safe the drug is over the long term and how well it controls symptoms like severe itching. Researchers will also track whether patients need surgery or a liver transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- odevixibat (Bylvay)
- What this could lead to
- If successful, this registry could confirm that odevixibat is safe and effective for long-term use in people with PFIC, supporting its continued use in routine care.
- What could go wrong
- This is a small observational registry (20 people) in China only, not a controlled trial. It may not prove cause and effect, and results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Capital Children's Medical Center
ACTIVE_NOT_RECRUITINGBeijing, China
-
Children's Hospital of Fudan University Endocrinology and Metabolism
RECRUITINGShanghai, China
-
Hunan Children's Hospital
RECRUITINGHunan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a bile acid blocker ease severe itching in a rare liver disease?
- New drug shows promise for babies with rare liver disorders
- Baby jaundice may leave lasting marks on teeth, new study investigates
- New drug livmarli tracked for Long-Term safety in kids with rare liver disorders
- Gene hunt for mysterious adult liver disease
- Liver drug maralixibat tested for Long-Term safety in rare disease patients